Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-time Targeted Enrichment in Single-cell Long-read Sequencing.

Genomics, proteomics & bioinformatics·2026
Same author

Next-generation sequencing using a targeted gene panel in advanced solid tumors: five years of experience from an Italian referral institution.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Loss of DNA-PK complex in recurrent pterygium suggests a role for defective double-strand break repair.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

A blood-based immune-suppressive index stratifies immunotherapy outcomes in advanced NSCLC.

Frontiers in immunology·2026
Same author

Technical feasibility of a long read, fourth generation sequencing platform in diagnostic profiling of clinical routine samples: a proof-of-concept study.

Pathologica·2026
Same author

Role of Maximum Standardized Uptake Volume in Predicting Tumor Spread Through Air Spaces in Stage IA Lung Cancers Smaller than 2 cm.

Cancers·2026
Same journal

IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment.

Oncology and therapy·2026
Same journal

Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape.

Oncology and therapy·2026
Same journal

Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): An Aggressive Disease Course and Limitations for Personalized Oncology.

Oncology and therapy·2026
Same journal

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL.

Oncology and therapy·2026
Same journal

Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene Panels.

Oncology and therapy·2026
Same journal

Evaluation of Drug-Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25).

Oncology and therapy·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K

Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience.

Francesco Pepe1, Gianluca Russo1, Alessandro Venuta1

  • 1Department of Public Health, Federico II University of Naples, Via S. Pansini, 5, 80131, Naples, Italy.

Oncology and Therapy
|January 10, 2024
PubMed
Summary
This summary is machine-generated.

Optimized diagnostic workflows using artificial reference specimens are crucial for advanced non-small cell lung cancer (NSCLC) patient management. These specimens help improve predictive molecular analysis in routine clinical practice.

Keywords:
LungMolecular pathologyTumor biomarker

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K

Related Experiment Videos

Last Updated: Jul 6, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Cancer Research

Background:

  • Biomarker testing is essential for managing advanced non-small cell lung cancer (NSCLC).
  • Various technical platforms exist for biomarker analysis, differing in multiplexing, sensitivity, and turnaround time.
  • Evaluating diagnostic workflow performance is critical for accurate patient care.

Purpose of the Study:

  • To assess the technical performance of diagnostic workflows in Italian institutions for NSCLC biomarker analysis.
  • To utilize artificial reference specimens to mimic routine diagnostic samples for evaluation.
  • To identify areas for optimization in molecular testing procedures.

Main Methods:

  • Distributed artificial reference specimens with specific mutations (EGFR, KRAS, ROS1, MET) to 24 Italian institutions.
  • Collected methodological and molecular data from participating centers.
  • Validated reference specimens independently before distribution.

Main Results:

  • Median DNA concentrations varied between automated (3.3 ng/µL) and manual (13.4 ng/µL) procedures.
  • Median RNA concentrations were 5.7 ng/µL (automated) and 9.3 ng/µL (manual).
  • High detection rates for KRAS, EGFR, and ROS1 alterations; MET exon 14 skipping detected in 93.7% of centers.

Conclusions:

  • Optimized technical workflows are vital for NSCLC patient decision-making.
  • Artificial reference specimens are effective tools for optimizing diagnostic workflows.
  • This approach enhances predictive molecular analysis in routine clinical practice.